(An active ingredient is what makes a drug work.) Keytruda is a biologic medication. A biologic is made from parts of living organisms. It’s available only as a brand-name drug. Keytruda isn’t ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

If you're patient, these businesses have a lot of promising projects in the works. Much to the chagrin of investors ... Merck ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

Pharmaceuticals firm Merck reported a solid third quarter on Thursday, with revenue up 4% year-over-year to $16.7bn, driven by robust sales of its cancer drug Keytruda, although muted demand for the ...

Keytruda is now under threat not only from patent ... And we've seen that with anti-VEGF, certainly, it seems to work better in East Asian population. I mean this is one country.